Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes.
Chairman and Chief Executive Officer Mike Cordonnier said the
Carlsmed (CARL) reported strong Q3 2025 results, beating revenue and EPS estimates with 98% YoY growth. The AI spine surgery firm also raised its full-year revenue guidance.
